Earnings Releases·Nov 4, 2026, 4:21 PM ET

Edwards Lifesciences — Third Quarter 2026 Earnings Summary

Q3 total sales rose 10.5% year-over-year to $1.72 billion, with adjusted EPS increasing 19% to $0.80; TMTT sales surged 44% to $207 million while TAVR grew 8% to $1.24 billion.
Management raised full-year 2026 guidance across all key metrics, projecting total sales growth of 11.5% (up from 10-11%) and adjusted EPS of $2.97–$3.05 (up from $2.95–$3.05).
Significant regulatory and clinical milestones included U.S. approval for PASCAL Precision in tricuspid repair and PASCAL Ace in degenerative mitral TEER, alongside new European approval for the EVOQUE system.
Capital allocation included $700 million in share repurchases through Q3, leaving $1.3 billion remaining under authorization, while the company maintains a strong balance sheet with $3.1 billion in cash and $600 million in debt.
Full-year adjusted gross profit margin is expected at the lower end of 78–79% due to currency headwinds, while adjusted operating margin is projected at the high end of 28–29%.